Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. by Leidig-Bruckner, Gudrun et al.
Leidig-Bruckner et al. BMC Endocrine Disorders 2014, 14:33
http://www.biomedcentral.com/1472-6823/14/33RESEARCH ARTICLE Open AccessPrevalence and determinants of osteoporosis in
patients with type 1 and type 2 diabetes mellitus
Gudrun Leidig-Bruckner1,2*, Sonja Grobholz2, Thomas Bruckner3, Christa Scheidt-Nave4, Peter Nawroth2
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Background: Increased risk of osteoporosis and its clinical significance in patients with diabetes is controversial. We
analyze osteoporosis prevalence and determinants of bone mineral density (BMD) in patients with type 1 and 2
diabetes.
Methods: Three hundred and ninety-eight consecutive diabetic patients from a single outpatient clinic received a
standardized questionnaire on osteoporosis risk factors, and were evaluated for diabetes-related complications,
HbA1c levels, and lumbar spine (LS) and femoral neck (FN) BMD. Of these, 139 (71 men, 68 women) type 1 and 243
(115 men, 128 women) type 2 diabetes patients were included in the study. BMD (T-scores and values adjusted for
age, BMI and duration of disease) was compared between patient groups and between patients with type 2
diabetes and population-based controls (255 men, 249 women).
Results: For both genders, adjusted BMD was not different between the type 1 and type 2 diabetes groups but
was higher in the type 2 group compared with controls (p < 0.0001). Osteoporosis prevalence (BMD T-score < −2.5
SD) at FN and LS was equivalent in the type 1 and type 2 diabetes groups, but lower in type 2 patients compared
with controls (FN: 13.0% vs 21.2%, LS: 6.1% vs 14.9% men; FN: 21.9% vs 32.1%, LS: 9.4% vs 26.9% women). Osteoporosis
prevalence was higher at FN-BMD than at LS-BMD. BMD was positively correlated with BMI and negatively
correlated with age, but not correlated with diabetes-specific parameters (therapy, HbBA1c, micro- and
macrovascular complications) in all subgroups. Fragility fracture prevalence was low (5.2%) and not different
between diabetes groups. Fracture patients had lower BMDs compared with those without fractures; however,
BMD T-score was above −2.5 SD in most patients.
Conclusions: Diabetes-specific parameters did not predict BMD. Fracture occurrence was similar in both diabetes
groups and related to lower BMD, but seems unrelated to the threshold T-score, <−2.5 SD. These results suggest
that osteoporosis, and related fractures, is a clinically significant and commonly underestimated problem in diabetes
patients.
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Although skeletal disorders in patients with diabetes melli-
tus have been reported, there is still controversy over the
risk of osteoporosis and its clinical significance in patients
with diabetes mellitus [1-3]. Many studies have demon-
strated osteopenia and increased fracture risk in patients* Correspondence: gudrun.leidigbruckner@raue-praxis.de
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article, unless otherwise stated.with type 1 diabetes, however the evidence for this risk in
type 2 diabetics is controversial [4-9]. Findings of increased
BMD and body weight, coupled with older epidemiological
studies suggesting no increase or even a decrease in frac-
ture risk led to speculation that patients with type 2 dia-
betes could have a decreased risk of osteoporosis [10].
However, recent epidemiological and clinical studies pro-
vide substantial evidence for an increased fracture risk in
patients with type 2 diabetes, despite an increased BMD or
independently of BMD [3,11-20]. Diabetes mellitus type 1
and type 2 are considered clinical risk factors within theCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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fracture probability [21].
The majority of older clinical studies focusing on dia-
betes mellitus and risk of osteoporosis are hampered by
methodological problems, such as: relatively small sam-
ple sizes; heterogeneous study populations; and the use
of different techniques and measurement sites for BMD.
Within epidemiological studies, the information on dia-
betes status is often limited to self-reports without pre-
cise information on diabetes classification or control
[1,2,20,22].
Osteoporosis and type 2 diabetes mellitus are com-
monly observed in the elderly population and will likely
increase in the future. Therefore, there is a need for fur-
ther investigation into the relationship between diabetes
and osteoporosis risk, and related fractures. The aim of
this study was to investigate the prevalence of osteopor-
osis (lumbar spine (LS) and femoral neck (FN) BMD
< −2.5 SD T-score) and of fragility fractures, as well as
determinants of BMD in a cohort of consecutive patients
with known type 1 and type 2 diabetes mellitus. The
prevalence of low BMD in patients with type 2 diabetes
was compared with a population-based control group of
the same age range living in the same area. Among pos-
sible determinants of LS-BMD and FN-BMD and risk of
osteoporosis, we focused on the influence of diabetes-
specific parameters like control of blood sugar, diabetes
therapy, duration of disease and presence of vascular
complications.
Methods
Patients
Diabetes group: A total of 398 patients with diabetes melli-
tus, comprising 155 patients with type 1 diabetes and 243
with type 2 diabetes were recruited consecutively from the
outpatient clinic at the University of Heidelberg. Recruit-
ment was performed as part of a cross-sectional, single-
center study, performed in the Heidelberg study center in
connection with the European Vertebral Osteoporosis
Study (EVOS), which was a multicenter study to determine
possible risk factors for osteoporosis [23,24]. Data collection
was performed during routine follow up visits for the con-
trol of diabetes between 12/1997–12/1999.
Control group: Participants in the EVOS within the
Heidelberg study center without a history of diabetes
mellitus were used as a control group. These were a suit-
able control group for our patients with type 2 diabetes
because they were a randomly selected population-based
sample living in the same region with the same age dis-
tribution as the patient group. This control group com-
prised 255 men and 249 women [25,26].
Ethical approval was obtained from the Ethics Com-
mittee of the Heidelberg University for the EVOS and
this additional study, including recruitment of diabeticpatients from our outpatient department. All partici-
pants and patients gave written informed consent.
Methods
Diabetes ascertainment and classification of diabetes
type:
Diagnosis of type 1 or type 2 diabetes was based on a re-
view of the patients’ medical records within the outpatient
clinic of the Department of Internal Medicine, Endocrin-
ology and Metabolism, University Hospital Heidelberg. The
classification of type 1 diabetes was based on: hypergly-
cemia and insulin deficiency requiring insulin treatment;
clinical course of disease with diabetic coma or other clin-
ical manifestations; and, in most patients, on additional la-
boratory findings (low insulin and low C-peptide serum
levels and positive GAD antibodies). There were 16/398
consecutive patients whose disease was classified as type 1
diabetes within the clinical records, who did not need insu-
lin treatment at the time of the study (either patients with
recently diagnosed diabetes or patients with longer duration
of diabetes who might be misclassified as type 1). These 16
patients without need of insulin treatment were excluded
from the present study. Therefore, the final study cohort
comprised 139 patients (71 men, 68 women) with type 1
diabetes.
Type 2 diabetes was defined by hyperglycemia (i.e.,
two consecutive fasting glucose levels ≥ 7.0 mmol/dl
(>100 mg/dl)) in combination with insulin resistance
(obesity). Furthermore, patients who required medica-
tion typically used for treatment of hyperglycemia in
type 2 diabetes (e.g. metformin) were classified as type 2
diabetics. Additional laboratory tests (insulin or C-
peptide levels or GAD-antibodies) were performed only
in those patients who could not be unequivocally classi-
fied by clinical parameters.
All diabetic patients were subjected to the standardized
questionnaire on general risk factors for osteoporosis and
for fragility fractures developed for the EVOS [26,27]. The
fracture related questions were detailed with respect to
location (vertebral, hip, wrist, rib and other fractures), frac-
ture occurrence (year) and trauma severity. A fracture oc-
curring spontaneously or after a fall from standing position
was defined as a low trauma fracture. Fractures occurring
after a fall from a higher position or caused by other
traumatic events were classified as traumatic fractures
and excluded from the analysis. Comorbidities and co-
medications were assessed through a standardized ques-
tionnaire examining the following parameters: surgical ther-
apies (gastric, intestinal, thyroid or parathyroid surgery;
ovariectomy); rheumatoid arthritis; hyperthyroidism; hyper-
parathyroidism; hypercortisolism; chronic liver diseases;
chronic gastrointestinal diseases; chronic renal diseases;
nephrolithiasis; chronic lung diseases and asthma. Co-
medication taken for longer than 3 months was recorded
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mone replacement therapy.
Furthermore, standardized questions on the history of
diabetes were included in the questionnaire (age at diag-
nosis of diabetes, diabetes specific therapy: diet, oral an-
tidiabetics including metformin, sulfonylurea, insulin).
We evaluated data from patient records regarding micro-
vascular and/or macrovascular complications. All respective
clinical investigations were performed during the routine
care of the patients within the diabetes department. With
respect to microvascular complications, the presence of dia-
betic nephropathy was evaluated by measurement of serum
creatinine and albumin excretion in morning spot urine by
standardized laboratory methods (albuminuria <20 mg/l
normal; 20–200 mg/l microalbuminuria, >200 mg/l macro-
albuminuria). Data on diabetic retinopathy were collected
from written reports from ophthalmologists and classified
as normal or pathological. The ophthalmologists did not
use a standardized protocol for classification of retinopathy
at the time when the study was performed. The
pathological findings included: maculopathy; proliferative
retinopathy; vitreous hemorrhage; and nonproliferative ret-
inopathy. Furthermore, we recorded whether laser therapy
was performed. The presence of polyneuropathy was deter-
mined by clinical investigation (measurement of vibration).
Macrovascular complications (coronary heart disease, myo-
cardial infarction, stroke, peripheral arterial disease) were
determined by reviewing patient records or, in cases where
no positive history had been recorded, by screening for car-
diological abnormalities (exercise test, echocardiography).
During clinical follow up, the following tests were per-
formed on all patients: blood pressure measurement; detec-
tion of peripheral pulse status; inspection of feet; a
neurological evaluation; and blood tests (blood sugar,
HbA1c, and lipid levels; renal function). Blood samples
were taken from all patients and stored at −80°C.
Bone mineral density (BMD) was measured at the LS
(L2–L4, LS) and at the FN by dual-energy x-ray absorpti-
ometry (DXA) using a Hologic 4500 bone densitometer.
Reference data provided by Hologic for Caucasian popula-
tions were used to compare the patients’ measurements
with age- and sex-matched normal BMD data and to calcu-
late T-scores, according to the WHO criteria [osteoporosis
(t-score < −2.5 SD), osteopenia (t-score from −1 to −2.5 SD)
and normal (t-score > −1 SD)] [28].
Statistical analysis
Descriptive statistics for continuous variables included
mean, median and standard deviation, categorical variables
were reported with absolute and relative frequencies. The
distribution of BMD was reported, stratified by gender and
diabetes type, for absolute measurements and T-scores. To
investigate the factors underlying the respective differences
between the type 1 and type 2 diabetes groups, we usedanalysis of covariance (ANCOVA), with age, body mass
index (BMI) and disease duration as covariates, to calculate
adjusted BMD values and reported the respective least
square means (LSMEANS) ± standard error (SE) for the
subgroups. Pearson correlation analyses were used to assess
the univariate relationship between BMD and risk factors.
In addition, multiple linear regression analysis was per-
formed to evaluate determinants of BMD, analyzed separ-
ately for type of diabetes. Age, gender, and BMI were
included in the model as known predictors of BMD, and in
addition, diabetic specific parameters (duration of diabetes,
HbA1c level and presence of micro- or macrovascular
complications) were considered. Logistic regression models
were used to assess determinants of osteoporosis defined
by T-score < −2.5 SD. Between-group differences were
tested using t-test or ANCOVA. The difference in preva-
lence rates of osteoporosis between the LS-BMD and FN-
BMD were analyzed using the McNemar test. Due to the
low prevalence of fragility fractures, all analyses referring to
fractures must be considered as descriptive and therefore
no multivariate analysis on fracture determinants was per-
formed. The level of significance was set to 5%. All statis-
tical calculations were carried out using SAS version 9.1.
Results
Clinical characteristics of the patients with diabetes mellitus
and the control group are described in Table 1 according to
diabetes type and gender. At the time of this study, patients
with type 1 diabetes were approximately 20 years younger
than those with type 2 diabetes (Table 1, Figure 1B) and the
BMI was significantly lower in type 1 than type 2 patients
(Table 1, p < 0.0001). Type 1 diabetes was diagnosed at a
younger age than type 2 diabetes, with around 15% of pa-
tients diagnosed during childhood (before 12 years of age),
presumably before the onset of puberty (Figure 1A). The
time since diagnosis (mean duration) of diabetes mellitus
was longer in patients with type 1 diabetes than in those
with type 2 diabetes (p < 0.001). Macrovascular complica-
tions including coronary heart disease, cerebrovascular
complications, and peripheral artery disease as well as
major comorbidities, such as hypertension, were more
likely to be present in patients with type 2 diabetes than in
those with type 1 diabetes. The presence of microvascular
complications was not uniformly distributed: polyneurop-
athy was more frequent in type 2 than in type 1 diabetes,
while retinopathy was more frequent in type 1 dia-
betes – especially the more severe forms of retinop-
athy (proliferative changes found in 17/137 (12.4%)
type 1 diabetes patients compared with 13/237 (5.5%)
in type 2 diabetes patients); no clear differences were
seen for nephropathy.
The distribution of comorbidities and co-medications
is summarized in the Additional file 1: Table S1. Among
patients with type 1 diabetes the majority of assessed
Table 1 Characteristics of patients and control group
Type 1 diabetes mellitus
(n = 139)
Type 2 diabetes mellitus
(n = 243)
Control group
(n = 504)
Men
(n = 71)
Women
(n = 68)
Men
(n = 115)
Women
(n = 128)
Men
(n = 255)
Women
(n = 249)
Mean ± SD
(Min. - max.)
Mean ± SD
(Min. - max.)
Mean ± SD
(Min. - max.)
Mean ± SD
(Min. - max.)
Mean ± SD
(Min. - max.)
Mean ± SD
(Min. - max.)
Age (years) 42.0 ± 12.9* 45.8 ± 13.0* 62.7 ± 8.5 62.9 ± 8.5 64.9 ± 8.4# 64.1 ± 8.0
(17–42) (22–79) (37–83) (28–87) (51–82) (51–81)
BMI (g/cm2) 25.2 ± 3.3* 24.6 ± 2.9* 28.9 ± 4.5 29.7 ± 5.3 27.6 ± 3.5## 26.9 ± 4.5##
(15.9–24.8) (18.9–32.0) (21.6–47.8) (18.9–47.3) (19–45) (16.8–42.1)
Age at menopause - (n = 13) - (n = 84) - (n = 198)
41.4 ± 6.2 46.6 ± 7.2 49.9 ± 4.7
(30–52) (27–58) (32–60)
Systolic blood pressure 127.8 ± 18.6 123.0 ± 17.2 136.8 ± 19.4 135.6 ± 21.1
(85–175) (90–125) (100–225) (80–190)
Diastolic blood pressure 74.9 ± 10.7 71.4 ± 10.2 76.2 ± 11.2 73.2 ± 11.9
(45–75) (55–95) (50.0–110.) (45–110)
Diabetes specific parameters
Age at first diagnosis of diabetes 26.4 ± 10.2* 25.1 ± 11.1* 51.9 ± 9.4 51.3 ± 11.9
(8–53) (1–55) (31–75) (20–80)
Duration of diabetes (years) 15.6 ± 12.0** 20.7 ± 12.2* 12 ± 9 11 ± 8
(0.2–44.0) (0.4–46.2) (0–34) (0–33)
HbA1c 7.09 ± 1.17 7.15 ± 1.07 7.22 ± 1.34 7.26 ± 1.19
(5.3–10.4) (4.7–10.4) (4.8–11.4) (4.9–11.1)
Diabetes therapy n (%) n (%) n (%) n (%)
Diet or oral antidiabetics 50 (43.5) 59 (46.1)
Insulin 71 100.0) 68 (100.0) 65 (56.5) 69 (53.9)
Microvascular complications
Retinopathy (n = 69) (n = 68) (n = 111) (n = 126)
No 41 (59.4) 42 (61.8) 86 (77.5) 86 (68.2)
Yes 28 (40.6) 26 (38.2) 25 (22.5) 40 (31.8)
Polyneuropathy (n = 70) (n = 67) (n = 115) (n = 128)
No 49 (70) 47 (70.2) 48 (41.7) 63 (49.2)
Yes 21 (30) 20 (29.8) 67 (58.3) 65 (50.8)
Nephropathy (n = 71) (n = 68) (n = 106) (n = 116)
Normal 50 (70.4) 55 (80.9) 61 (57.6) 81 (69.8)
Microalbuminuria 15 (21.1) 12 (17.7) 35 (33.0) 26 (22.4)
Macroalbuminuria 6 (8.5) 1 (1.4) 10 (9.4) 9 (7.8)
Macrovascular complications
Coronary heart disease (n = 66) (n = 65) (n = 108) (n = 123)
No 58 (87.9) 60 (92.3) 77 (71.3) 100 (81.3)
Yes 8 (12.1) 5 (7.7) 31 (28.7) 23 (18.7)
Myocardial infarction 6 (8.5) 2 (2.9) 24 (20.9) 16 (12.5)
Cerebrovascular disease
(Stroke, TIA, PRIND) 2 (2.9) 0 (0) 6 (5.2) 7 (5.5)
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Table 1 Characteristics of patients and control group (Continued)
Peripheral artery disease (n = 68) (n = 68) (n = 111) (n = 124)
No 62 (91.2) 63 (92.6) 91 (82.0) 105 (84.7)
Yes 6 (8.8) 5 (7.4) 20 (18.0) 19 (15.3)
Hypertension
yes 27 (38.0) 21 (30.9) 83 (72.2) 97 (75.8)
Comparison between type 1 and type 2 diabetes groups by gender: *p < 0.0001; **p < 0.001.
Comparison between type 2 diabetes group with control group by gender: #p < 0.02, ##p < 0.006.
TIA (transient ischemic attack); PRIND (prolonged ischemic neurological deficit).
Leidig-Bruckner et al. BMC Endocrine Disorders 2014, 14:33 Page 5 of 13
http://www.biomedcentral.com/1472-6823/14/33comorbidities were rarely reported (prevalence less than
5%). However, hyperthyroidism, rheumatoid arthritis and
chronic lung disease were each reported in up to 10% of
the women. For both men and women with type 2 dia-
betes, a history of rheumatoid arthritis, hyperthyroidism,0
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Figure 1 Distribution of age at time of diagnosis of diabetes
subgrouped by type 1 and type 2 diabetes (A) and distribution
of age at time of study performance (B).nephropathy or chronic lung disease was reported in
5–15% of patients. Use of glucocorticoids was reported
in 6–12.5% and antacids were used by 6.5–18.6% of
patients.
Distribution of BMD in patients with type 1 and type 2
diabetes
Figure 2 illustrates the age and sex specific distributions
of FN-BMD in patients with type 1 and type 2 diabetes
in relation to the respective reference distributions. Men
and women with type 1 diabetes had BMD values usu-
ally within the reference range and the linear regression
lines fitted to the data did not significantly differ from
the mean reference curve values. In contrast, patients
with type 2 diabetes had significantly higher mean FN-
BMD compared with the mean reference values. Similar
distributions were found for LS-BMD in all subgroups
(data not shown).
The comparison of BMD values between patients with
type 1 and type 2 diabetes mellitus and the control
group is shown, stratified by gender, in Tables 2 and 3
(absolute measurements, T-scores and adjusted BMD
values). Age-adjusted mean BMD at the FN was signifi-
cantly lower in men and women with type 1 diabetes
compared with those with type 2 diabetes (p = 0.0004
and p = 0004). A similar trend was found for BMD at
the LS, while the differences were smaller and reached
significance only in women (p = 0.02). However, when
BMD values were adjusted for age, BMI and duration of
disease, the adjusted values were not different between
patients with type 1 and type 2 diabetes. In contrast, in
both male and female patients with type 2 diabetes, the
adjusted BMD values remained significantly higher at
the FN and LS compared with the age-matched control
group.
Prevalence of osteoporosis in patients with diabetes
compared with the control group
The prevalence of osteoporosis, osteopenia and normal
BMD in patients with diabetes and the control group
based on femoral BMD and LS-BMD measurements is
summarized in Tables 2 and 3, stratified by gender. No
difference was observed between men and women with
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Figure 2 Distribution of femoral neck bone mineral density (BMD) subgrouped according to type of diabetes and gender in
comparison to the normal distribution (Hologic reference population, mean ± 2 SD).
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FN (9.9% of men and 10.3% of women). However,
women with type 2 diabetes had a higher prevalence
(21.9%) than men with type 2 diabetes (13.0%). The re-
spective prevalence of osteoporosis at the LS was 5.6%
in men and 5.9% in women with type 1 diabetes and
6.1% in men and 9.4% in women with type 2 diabetes.
The proportion of patients with osteoporosis at the FN
(T-score < −2.5 SD) was higher compared with the pro-
portion of patients with osteoporosis at the LS in all
groups, however this difference only reached statistical
significance in patients with type 2 diabetes (p = 0.03 in
men, p = 0.001 in women).
The prevalence of osteoporosis was significantly lower
at both measurement sites in patients with type 2 dia-
betes in comparison with the age-matched, population-
based control group (LS-BMD: men 14.9%, women
26.9%; FN-BMD: men 21.2%, women 32.1%). The risk of
having osteoporosis according to BMD criteria was ap-
proximately halved in patients with type 2 diabetes com-
pared with the control group [LS-BMD Odds ratio (95%
CI): men 0.36 (0.16–0.83); women 0.28 (0.14–0.53) and
FN-BMD Odds ratio (95% CI): men 0.52 (0.28–0.97);
women 0.59 (0.36–0.97)].Determinants of BMD in patients with type 1 and type 2
diabetes
We observed a significant and positive correlation between
BMI and FN-BMD. The correlation was more pronounced
in men and women with type 2 diabetes (r = 0.37,
p < 0.0001 and r = 0.44, p <0.0001) than men and women
with type 1 diabetes (r = 0.24, p <0.04 and r = 0.20, p <0.09).
Duration of diabetes and FN-BMD were significantly and
negatively correlated in women with type 1 diabetes
(r = −0.34, p < 0.005) but not in men with type 1 diabetes
(r = −0.18, p < 0.13) and not in patients with type 2 diabetes
(r = −0.11, p = 0.2 in women, r = −0.15, p = 0.1 in men).
HbA1c levels were not correlated with BMD in any sub-
group (type 1 diabetes: women: r = −0.03, men: r = −0.03;
type 2 diabetes: women: r = −0.076, men: r = −0.07). Fur-
thermore, there was no difference in BMD between women
with type 2 diabetes treated with diet, oral antidiabetics or
insulin therapy, but BMD was lower in men with type 2
diabetes undergoing insulin treatment (LSMEAN± SE; FN-
BMD 0.86 ± 0.02 g/cm2; LS-BMD 1.035 ± 0.02 g/cm2)
compared with those treated with other therapies (FN-
BMD 0.91 ± 0.02 g/cm2; LS-BMD 1.13 ± 0.02 g/cm2) (p =
0.02; p = 0.004). Age-adjusted FN-BMD was compared with
respect to the presence of micro- or macrovascular
Table 2 Distribution of bone mineral density (BMD) in patients with type 1 and type 2 diabetes mellitus and the
control group by gender (men)
Men
Type 1 n = 71 Type 2 n = 115 Control n = 255 Type 1 vs. type 2 Type 2 vs. control
BMD Mean ± SD Mean ± SD Mean ± SD p-value p-value
Lumbar BMD (g/cm2) 1.05 ± 0. 14 1.08 ± 0.18 1.03 ± 0.20 0.263 0.03
Femoral Neck BMD (g/cm2) 0.84 ± 0.12 0.88 ± 0.15 0.81 ± 0.13 0.079 0.0001
T-Score (SD) Lumbar BMD −0.56 ± 1.34 −0.31 ± 1.61 −0.76 ± 1.78 0.268 0.017
T-Score (SD) Femoral Neck BMD −1.20 ± 1.11 −0.90 ± 1.39 −1.55 ± 1.24 0.104 0.0001
Adjusted BMD* LSMEAN ± SE LSMEAN ± SE LSMEAN ± SE
Lumbar BMD (g/cm2) 1.05 ± 0.03 1. 08 ± 0.02 1.03 ± 0.01 0.453 0.027
Femoral Neck (g/cm2) 0.83 ± 0.02 0. 88 ± 0.02 0.81 ± 0.01 0.11 0.0011
WHO-criteria % (n) % (n) % (n)
Lumbar BMD T-score
<−2.5 SD (Osteoporosis) 5.6 (4) 6.1 (7) 14.9 (38)
−2.5 SD – −1.0 SD (Osteopenia) 31.0 (22) 30.4 (35) 32.9 (84)
>−1.0 SD (Normal) 63.4 (45) 63.5 (73) 52.2 (133)
WHO-criteria
Femoral Neck BMD T-score
<−2.5 SD (Osteoporosis) 9.9 (7) 13.0 (15) 21.2 (54)
−2.5 SD – −1.0 SD (Osteopenia) 45.1 (32) 35.7 (41) 49.8 (127)
>−1.0 SD (Normal) 45.1 (32) 51.3 (59) 29.0 (74)
SD = Standard deviation.
LSMEAN = Least Square Mean (age adjusted BMD-values), SE = Standard Error.
*Adjusted for age, duration of diabetes and BMI.
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women with type 1 diabetes, there was a tendency for lower
BMD values in patients with coronary heart disease than in
those without coronary heart disease (FN-BMD LSMEAN
0.73 ± 0.05 g/cm2 vs. 0.80 ± 0.013 g/cm2; p = 0.13). The re-
spective differences were only marginal within the other
subgroups. None of the other micro- and macrovascular
complications (retinopathy, polyneuropathy, nephropathy,
peripheral artery disease), showed a relationship to BMD
(data not shown, available on request).
Multiple linear regression analyses were performed to
identify determinants of LS-BMD and FN-BMD in pa-
tients with type 1 and type 2 diabetes (detailed results
see Table 4). In patients with type 1 diabetes, only age
and BMI were significantly associated with LS-BMD and
FN-BMD, while diabetes-specific variables (duration of
diabetes, HbA1c level, presence of vascular complica-
tions) showed no significant influence. In patients with
type 2 diabetes, LS-BMD was significantly determined
by gender, age, BMI and duration of diabetes, while FN-
BMD was dependent on gender, age and BMI. Similar
results were found within a multivariable logistic regres-
sion analysis to identify determinants of a FN-BMD
below a T-score of −2.5 SD. Age was the only significant
predictor of a FN-BMD below T-score of −2.5 SD inpatients with type 1 diabetes, while in type 2 diabetes,
age and BMI were significantly associated with a low
BMD.
Fracture history in type 1 and type 2 diabetes
Information on fracture history was complete in 85% of
our diabetic patients (n = 325). Traumatic fractures were
reported in 12 patients (3 rib fractures, 4 wrist and 7
other fractures (note some patients had multiple frac-
tures)) - these fractures were excluded from further ana-
lysis. At least one low trauma fracture was reported for
17 patients after diabetes was confirmed. The mean time
between diagnosis of diabetes and fracture occurrence
was 10.3 ± 8.5 years in patients with type 1 and 5.8 ±
6.7 years in patients with type 2 diabetes. In these 17 pa-
tients, a total of 22 low trauma fractures were reported
and distributed as follows: two vertebral, one hip, four
rib, four wrist, and 11 other fractures. The overall preva-
lence of persons with a history of low trauma fracture
(17/325, 5.2%) did not significantly differ according to
gender or type of diabetes [type 1 diabetes: men 4/63
(6.4%); women 4/63 (6.4%); type 2 diabetes: men 3/94
(3.2%); women 6/105 (5.7%)].
The distribution of FN-BMD and LS-BMD (T-scores)
subgrouped into patients with and without fractures by
Table 3 Distribution of bone mineral density (BMD) in patients with type 1 and type 2 diabetes mellitus and the
control group by gender (women)
Women
Type 1 n = 68 Type 2 n = 128 Control n = 249 Type 1 vs. type 2 Type 2 vs. control
BMD Mean ± SD Mean ± SD Mean ± SD p-value p-value
Lumbar BMD (g/cm2) 1.03 ± 0.15 1.02 ± 0.17 0.90 ± 0.18 0.733 0.0001
Femoral Neck BMD (g/cm2) 0.80 ± 0.12 0.79 ± 0.16 0.70 ± 0.12 0.940 0.0001
T-Score (SD) Lumbar BMD −0.45 ± 1.37 −0.46 ± 1.56 −1.65 ± 1.53 0.974 0.0001
T-Score (SD) Femoral Neck BMD −1.01 ± 1.15 −0.95 ± 1.57 −1.96 ± 1.13 0.772 0.0001
Adjusted BMD* LSMEAN ± SE LSMEAN ± SE LSMEAN ± SE
Lumbar BMD (g/cm2) 1.01 ± 0.03 1.05 ± 0.01 0.91 ± 0.01 0.337 0.0001
Femoral Neck (g/cm2) 0.78 ± 0.02 0.80 ± 0.01 0.71 ± 0.01 0.560 0.0001
WHO-criteria % (n) % (n) % (n)
Lumbar BMD T-score
<−2.5 SD (Osteoporosis) 5.9 (4) 9.4 (12) 26.9 (67)
−2.5 SD – −1.0 SD (Osteopenia) 29.4 (20) 27.3 (35) 42.6 (108)
>−1.0 SD (Normal) 64.7 (44) 63.3 (81) 30.5 (76)
WHO-criteria
Femoral Neck BMD T-score
<−2.5 SD (Osteoporosis) 10.3 (7) 21.9 (28) 32.1 (80)
−2.5 SD – −1.0 SD (Osteopenia) 41.2 (28) 31.2 (40) 45.8 (114)
>−1.0 SD (Normal) 48.5 (33) 46.9 (60) 22.1 (55)
SD = Standard deviation.
LSMEAN = Least Square Mean (age adjusted BMD-values), SE = Standard Error.
*Adjusted for age, duration of diabetes and BMI.
Table 4 Multiple linear regression analyses of determinants of bone mineral density (BMD) in patients with type 1 and
type 2 diabetes
Diabetes mellitus type 1
Dependent variable: lumbar BMD Dependent variable: femoral neck BMD
Parameter estimate; SE p-value Parameter estimate; SE p-value
Gender (women vs. men) 0.0050; 0.02 0.84 −0.019; 0.02 0.32
Age −0.0025; 0.001 0.04 −0.003; 0.0009 0.0004
Duration of diabetes −0.0009; 0.001 0.51 −0.0009; 0.001 0.51
BMI 0.013; 0.004 0.001 0.011; 0.003 0.0003
Presence of micro- or macrovascularcomplications 0.004; 0.03 0.88 0.022; 0.02 0.38
HbA1c −0.02; 0.01 0.08 −0.008; 0.008 0.37
Diabetes mellitus type 2
Dependent variable: lumbar BMD Dependent variable: femoral neck BMD
Parameter estimate; SE p-value Parameter estimate; SE p-value
Gender (women vs. men) −0.05; 0.02 0.02 −0.079; 0.02 0.0001
Age −0.003; 0.001 0.02 −0.003; 0.001 0.001
Duration of diabetes 0.004; 0.001 0.01 0.00047; 0.001 0.704
BMI 0.007; 0.002 0.002 0.010; 0.002 0.0001
Presence of micro- or macrovascularcomplications −0.0006; 0.03 0.98 −0.016; 0.02 0.51
HbA1c −0.0126; 0.008 0.15 −0.01; 0.007 0.14
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http://www.biomedcentral.com/1472-6823/14/33type of diabetes is shown in Figure 3. There was a trend
for lower BMD values in patients with fractures com-
pared with those without fractures in all subgroups,
however BMD showed a remarkable overlap between
patients with fractures and those without and most pa-
tients with fractures had T-scores above −2.5 SD. In pa-
tients with type 1 diabetes, LS-BMD and FN-BMD were
significantly lower in those with fractures compared withyes no yes no
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Figure 3 Distribution of bone mineral density (BMD) (Box-plots)
in patients with and without insufficiency fractures subgrouped
by type of diabetes mellitus; T-score femoral neck BMD (upper
part), T-score lumbar spine BMD (lower part).those without fractures (LS-BMD p <0.02 and FN-BMD
p < 0.03) while in patients with type 2 diabetes there was
a similar trend which did not reach statistical signifi-
cance (LS-BMD p < 0.2 and FN-BMD p < 0.2). Age, BMI,
diabetes duration and HbA1c levels were not different
between patients with and without fractures, subgrouped
by diabetes type. The occurrence of fractures was not
significantly different between men and women and
showed no association with the presence of vascular
complications in patients with type 1 and type 2
diabetes.
Discussion
Distribution of BMD in patients with type 1 and type 2
diabetes
In summary, our study shows that the prevalence of low
BMD and fractures was similar in patients with type 1
and type 2 diabetes, although patients with type 1 were
about 20 years younger than those with type 2 diabetes.
The comparison of BMD distribution with a population-
based control group suggests a lower risk of osteoporosis
in type 2 diabetes. However, the prevalence of fragility
fractures was not different between patients with type 1
(6.4%) and type 2 diabetes (4.5%). In both diabetic
groups, we found lower BMD values at the FN than at
the LS. Determinants of BMD were body mass index
and age, but not diabetes specific parameters including
diabetes control (HbA1c level), duration and vascular
complications. Occurrence of low trauma fracture was
related to lower BMD values, however most patients
with fractures had BMD-values above a threshold of T-
score of −2.5 SD.
Our finding of lower FN-BMD than LS-BMD in patients
with diabetes is in agreement with some studies, while
others did not find such a difference [6,9,29-32]. Most stud-
ies focus on either type 1 or 2 diabetes, or do not precisely
define the diabetes type at all and, thus, the assessment of a
cohort of consecutive patients of both diabetes types is
unique to our study. The increased bone loss at the FN
compared with the LS-BMD suggests that osteoporosis in
diabetic patients preferentially develops within the appen-
dicular skeleton with predominantly cortical bone. One
possible explanation could be the presence of secondary
hyperparathyroidism due to vitamin D deficiency, as PTH
causes predominantly cortical bone loss. However, this
needs further investigation. Another explanation for in-
creased LS-BMD values in patients with type 2 diabetes
could be an artificially high determination of BMD due to
degenerative changes and diffuse idiopathic skeletal hyper-
ostosis, frequently found in such patients [33-36]. Although
the reasons for the divergent distribution of bone mass at
the FN and LS cannot be clarified by our study, this finding
is of practical relevance and suggests that evaluation of
osteoporosis risk in diabetic patients should include both
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ment of the forearm with predominantly cortical bone
should also be included.
The increased LS-BMD and FN-BMD found in our
patients with type 2 diabetes in comparison with a
population-based control group confirms similar find-
ings from epidemiological studies. There is growing evi-
dence for an increased risk of fractures in patients with
diabetes mellitus despite normal or even high BMD
values [3,16,37]. Although our study size was not pow-
ered for the assessment of fracture determinants, and
the number of patients with fragility fracture was rela-
tively low, it was evident that patients with fractures had
significantly lower (type 1 diabetes) or a trend towards
lower (type 2 diabetes) BMD values than patients with-
out fractures. However, BMD values were above the T-
score of −2.5 SD in most patients with fractures. This
suggests that there is an association between fracture
risk and BMD in diabetic patients, but the fracture
threshold is higher than that associated with non-
diabetic populations (T-score < −2.5 SD). Our data sup-
port findings of a recent epidemiological study on the
association between BMD, FRAX-score and fracture risk
in older adults with diabetes [22], showing that the level
for increased fracture risk seems to be about 0.5 SD
T-Score higher than in nondiabetics. In contrast,
Yamamoto et al., found no relationship between fracture
risk and BMD in diabetic patients, although the rate of
fractures was rather high (30%) in this study, suggesting
some selection bias [19]. Both studies [19,22] focus on
patients with type 2 diabetes, while association studies
on fracture risk and BMD in patients with type 1 dia-
betes are rare [3]. The relatively high rate of low trauma
fractures and of low BMD found in our patients with
type 1 diabetes mellitus with a median age of 45 years,
underlines the clinical importance of changes in bone
metabolism as a complication associated with type 1 dia-
betes mellitus that is probably underestimated and de-
serves more consideration during patient care.
Predictors of BMD and fractures in type 1 and 2 diabetes
The assessment of diabetes specific parameters and
osteoporosis only showed some weak relationships, and
our data did not permit the reliable prediction of the risk
of low BMD (T-score < −2.5 SD) or the occurrence of
low trauma fractures from clinical parameters. There
was a weak negative correlation between diabetes dur-
ation and FN-BMD in type 1 but not in type 2 diabetes.
A lack of insulin is speculated to exert a negative influ-
ence on bone formation resulting in a decreased peak
bone mass in patients with type 1 diabetes, as the dis-
ease often starts at a time when peak bone mass is not
yet achieved [38,39]. About 15% of our patients with
type 1 diabetes were diagnosed before puberty. Furtherlongitudinal studies are required to assess the influence
of diabetes onset before or after puberty on the develop-
ment of peak bone mass and risk of osteoporosis during
later life. In patients with type 2 diabetes the type of
therapy (diet, oral antidiabetics, insulin) was not related
to the risk of osteoporosis in women, while men with in-
sulin therapy had slightly lower BMD values. None of
our patients were treated with thiazolidinedione, so this
known risk factor for osteoporosis was not relevant in
our analysis.
We investigated the contribution of several comorbidities
and co-medications known to influence bone health – the
prevalence was low (<5%) for most of these factors within
our patient groups, with a number reported between 5 and
15%. However, the frequencies of affected patients were not
different between subgroups. As the number of affected pa-
tients was so low, it was not feasible to consider these as-
pects within multivariate analysis.
One aim of our study was to assess the relationship
between the occurrence of micro- and macrovascular
complications and the risk of osteoporosis. We found no
significant relationship between vascular complications
and BMD. However, in female type 1 diabetes patients,
there was a trend for lower FN-BMD in patients with
coronary heart disease than in those without. This sup-
ports the hypothesis that vascular changes and compli-
cations influence bone metabolism and contribute to the
development of osteoporosis as long suggested by histo-
pathological studies of bone biopsies [40] and from stud-
ies showing an association between atherosclerosis and
low bone mineral density [41-45].
In a multivariate model, only age and BMI were sig-
nificant predictors of BMD in type 1 diabetes, while in
type 2 diabetes, gender was also predictive for BMD,
probably reflecting the higher prevalence of postmeno-
pausal status within this subgroup. Neither gender, nor
parameters of disease control (such as HbA1c levels,
therapy regimen (oral antidiabetics vs. insulin), duration
and complications of diabetes), predicted BMD. Schwarz
et al., had shown that insulin treatment increased the
risk of falls, which probably contributes to the increased
fracture risk [46].
Due to the study size and the relatively low number of
fragility fractures, our data does permit the assessment of
fracture determinants by a multivariate model. In both dia-
betes groups, the mean BMD values were lower in patients
with fragility fractures compared with those without. How-
ever, there was a remarkable overlap between patients with
and without fractures, and in most patients with fractures,
the BMD was above the fracture threshold of −2.5 SD T-
score. Possible reasons for the increased bone fragility inde-
pendent of BMD include changes in bone structure and
bone quality caused by hyperglycemia and the accumula-
tion of advanced glycated end products (AGES) of bone
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with concomitant longer period of potential hyperglycemia
in type 1 diabetes mellitus may be associated with fracture
risk independently of BMD. Furthermore, several non-
skeletal factors may be related to fracture risk, such as an
increased propensity of falls, secondary to diabetic compli-
cations like visual impairment or neuropathy [2,15,46].
Although most low trauma fractures recorded in our
patients were not located at the skeletal sites considered
typical for osteoporosis, like vertebrae or hip, they are of
clinical importance as these fractures are known to ac-
count for 80% of the clinical fractures especially in youn-
ger patients, and may precede a hip fracture [47]. The
association of these low trauma fractures at any site to a
lower BMD in our diabetic patients supports these as
being “osteoporotic” fractures. In clinical practice, the
occurrence of any low trauma fracture in diabetic pa-
tients should be closely monitored, to identify those pa-
tients who are at increased risk for further fractures, and
to initiate diagnostic evaluation for osteoporosis and
therapy.
Strengths and limitations
The strength of our study is the standardized evaluation
of diabetic patients including a questionnaire of possible
osteoporosis risk factors and BMD measurements, which
applied the same regimen as a population-based study
on osteoporosis (EVOS), performed within a similar time
period and region, and used as a control group for the
type 2 diabetes patient group. We were able to assess a
relatively large, unselected cohort of consecutive patients
with type 1 and type 2 diabetes with a nearly equally dis-
tributed number of men and women, allowing a com-
parison between the respective subgroups. In all diabetic
patients, standardized documentation of diabetes-related
parameters including type of diabetes, diabetes therapy,
control and diabetes-related vascular complications was
available, ensuring a high data quality. One limitation is
the lack of an adequate control group for the type 1 dia-
betes patient group, due to the age difference between
the population-based control group and most patients
with type 1 diabetes, although this limitation was mini-
mized through adjustment of BMD values according to
age, BMI and duration of diabetes. A second limitation
is the relatively small sample size of diabetic patients in
this study with respect to the complex questions
addressed, especially when stratified by diabetes type
and gender. Thus, our findings have to be considered
descriptive.
A third limitation of our study is the cross-sectional
design, which restricts the assessment of causal relation-
ships. Furthermore, data on low trauma fractures were
only based on a questionnaire and patient records. Non-
skeletal parameters such as the risk of falls, includingmuscle weakness, dizziness and cerebrovascular diseases
are major determinants of fractures in addition to BMD
and were not assessed within the present study. Finally,
the relatively low number of patients with fragility frac-
tures limits conclusive statistical analysis, especially re-
garding fracture occurrence.
Conclusion
Our study shows a similar risk of osteoporosis in patients
with type 1 diabetes based on low BMD (T-score < −2.5
SD), which was not different from the prevalence in pa-
tients with type 2 diabetes despite them being approxi-
mately 20 years older. The FN-BMD was particularly
decreased; therefore evaluation of osteoporosis risk in
younger patients with type 1 diabetes should include both
spinal and FN-BMD-measurements.
In agreement with others, we found increased LS-
BMD and FN-BMD in patients with type 2 diabetes in
comparison with a non-diabetic population-based con-
trol group. There was a trend for lower BMD in diabetic
patients (type 1 and 2) with osteoporotic fractures com-
pared with those without fractures, however the fracture
threshold is higher than in non-diabetic populations.
Further longitudinal cohort studies are required, focus-
ing on the risk of fractures and changes in bone metab-
olism in patients with diabetes. BMD measurements and
the evaluation of BMD-independent risk factors for frac-
tures should be included in the routine management of
patients with diabetes mellitus because the prediction of
osteoporosis solely by clinical diabetes-specific parame-
ters was not possible. The evidence suggests that osteo-
porosis, and related fractures, is a clinically significant
and commonly underestimated problem in patients with
type 1 and type 2 diabetes mellitus.
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